PPT-Hypertensive disorders of pregnancy and CKD

Chrysostomos Dimitriadis MD PhD Nephrologist 1 st Department of Nephrology Aristotles University of Thessaloniki Hippokration General Hospital Thessaloniki Greece. Josh Exley. Learning Objectives. Acute Kidney Injury. Drugs and the Kidney. Chronic Kidney Disease. Normal Kidney function. Kidney Functions. Excretory function. Filter metabolites, toxins, drugs. Homeostatic function. Jonathan Elliott. Royal Veterinary College. London. Landmarks for feline hypertension research at the RVC. 1992 first BSAVA Clinical Studies Trust Fund grant awarded (Penney Barber appointed - PhD). 1993 Measurement of ionised calcium using electrode methods – is low ionised calcium related to feline hypertension?. Metformin must be considered the cornerstone of treatment when not contraindicated (eGFR <30). In patients not at goal on metformin monotherapy, adding an SGLT. 2. inhibitor like empagliflozin is warranted when not contraindicated (eGFR <45). ( ) CVD benefit ?Class effect?. Program Goals. Hepcidin in Chronic Kidney Disease. Treatment of Iron Deficiency Anemia. Assessment of IV Iron in Patients With Non-Dialysis-Dependent CKD. DOPPS Study. Ferric Pyrophosphate. Phosphate Binders. 2017 . Annual Data Report. Volume 1: Chronic Kidney Disease. 2. vol 1 Figure 7.1 Sources of prescription drug coverage in Medicare enrollees, by population, 201. 5. Data source: Medicare 5% sample. Point prevalent Medicare enrollees alive on January 1, 2015. Abbreviations: CKD, chronic kidney disease; LIS, Medicare Low-income Subsidy; Part D, Medicare prescription drug coverage benefit.. Learning Objectives. Facilitate timely testing and intervention in patients at-risk for chronic kidney disease (CKD).. Apply appropriate . clinical measures . to manage risk and increase . patient . safety in CKD.. Case 201-cv-00779-WBS -CKD Document 142 Filed 04/29/05 Page 2 of 2123456789-1- RD 1234567892 R Namita Singh, MD, FASN. Year 2021. DISCLOSURES. I have no financial relationships with commercial interests to disclose.. This presentation does not include discussion of off-label or investigational use. . . Structural . or functional abnormalities of the kidneys for . >. 3 months. . from early to late-stage disease, . Chronic Kidney Disease. as . manifested by either:. 1. Kidney . damage, with or without decreased GFR, as . Hyperkalemia, Metabolic Acidosis, Malnutrition, Depression & Acute Kidney Injury. Andrew . Narva. , MD, FASN & . Amy Barton . Pai. , PharmD, MHI, FASN, FCCP, FNKF. Andrew . Narva. , MD, FASN. Ingrid Berling. 29/09/2010. Aims. Epidemiology/pathophysiology. Definitions/common types. Clinical evaluation. Goals of treatment. Pharmacotherapy. Specific treatment. Epidemiology. Prevalence . of hypertension in Australia is 11%. In CKD and HD patients dysfunction of . immu. ne . sy. stem . a. lterations. . belonge. to . . involv. ing. . i. nnate. and . a. daptive. . i. mmunity. in T and B lymphocytes (. Reduced . T regulatory cells and memory cells and increased innate cells). . Harshani D. Perera . Senior Registrar – Nephrology. SJGH . 09.01.2018. CKD – definition . Kidney damage or eGFR < 60 ml/min/1.73m2 persisting for 3 months despite the cause . several classifications . Konstantia. Ass. Prof. of Nephrology D.U.TH.. Reduced quality of life . van Haalen et al. BMC Nephrology 2020. Worse renal survival. Lamerato et al. BMC Nephrology 2022. Increase in morbidity and mortality.